A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Favipiravir in Adult Subjects With Uncomplicated Influenza (T705US316)

Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Favipiravir in Adult Subjects With Uncomplicated Influenza (T705US316)

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Jun 2016

At a glance

  • Drugs Favipiravir (Primary)
  • Indications Influenza A virus infections; Influenza B virus infections
  • Focus Registrational; Therapeutic Use
  • Acronyms FAVOR
  • Sponsors FujiFilm Pharmaceuticals USA; MDVI
  • Most Recent Events

    • 31 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Feb 2015 Planned End Date changed from 1 Feb 2015 to 1 Oct 2015, as reported by ClinicalTrials.gov.
    • 25 Feb 2015 Planned primary completion date changed from 1 Feb 2015 to 1 May 2015, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top